The Chase Group is pleased to announce the successful completion of the Director, Clinical Research, Neuroscience at Eisai Inc. The successful candidate is a Board Certified Neurologist with Certifications in Epilepsy, Sleep Medicine and Clinical Neurophysiology. We wish this candidate the best of success as she begins her career at Eisai reporting directly to the Chief Medical Officer of the Neurology Business Group. The Chase Group appreciates and values our continued partnership with Eisai and would like to congratulate them on securing an exceptional physician for their team. We are proud to connect life-changing executives and companies!
A Successful Placement at Eisai, Inc.
The Chase Group is pleased to announce the successful completion of the Director, Clinical Research, Neuroscience at Eisai Inc. The successful candidate is a Board Certified Neurologist with Certifications in Epilepsy, Sleep Medicine and Clinical Neurophysiology. We wish this candidate the best of success as she begins her career at Eisai reporting directly to the Chief Medical Officer of the Neurology Business Group. The Chase Group appreciates and values our continued partnership with Eisai and would like to congratulate them on securing an exceptional physician for their team. We are proud to connect life-changing executives and companies!- Categories: Life Sciences, Research & Development
Ionis Director, Global HEOR, Rare Disease Immunology, Successfully Placed by The Chase Group
Ami Claxton, MS, PhD has joined Ionis Pharmaceuticals, Inc. as Director, Global HEOR Rare Disease Immunology. She will play a critical and significant role as…
Successful Placement at Avidity
The Chase Group is pleased to announce the successful completion of the Vice President, Medical Affairs search for Avidity Biosciences. Nathan Weedin brings 15+ years…
The Chase Group Successfully Completes Search for Amyloidosis Medical Affairs Leader
Ionis Pharmaceuticals has a 35-year track record of perfecting and advancing RNA-targeted drug discovery and development. Projecting a vast number of new transformational products on…
The Chase Group Identifies Chief Medical Officer for Arcturus Therapeutics
In late 2022, Arcturus Therapeutics retained The Chase Group to build out additions to the leadership team. Tasked with identifying the new Chief Medical Officer,…
The Chase Group Secures VP, Head of Regulatory Affairs, for Checkmate Pharmaceuticals
The Chase Group is pleased to announce the successful recruitment of Elvis Osei Tutu, PharmD, as the Vice President, Head of Regulatory Affairs at Checkmate…
The Chase Group Secures Clinical Operations Leadership for Alexza Pharmaceuticals
The Chase Group, committed to executive recruitment in life sciences, is pleased to announce the completion of another search for Alexza Pharmaceuticals, successfully securing Mike…